KR20240024175A - 피부 신경섬유종의 치료에 사용하기 위한 니트록솔린 - Google Patents
피부 신경섬유종의 치료에 사용하기 위한 니트록솔린 Download PDFInfo
- Publication number
- KR20240024175A KR20240024175A KR1020247000745A KR20247000745A KR20240024175A KR 20240024175 A KR20240024175 A KR 20240024175A KR 1020247000745 A KR1020247000745 A KR 1020247000745A KR 20247000745 A KR20247000745 A KR 20247000745A KR 20240024175 A KR20240024175 A KR 20240024175A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- nitroxolin
- treatment
- cells
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2108224.3A GB202108224D0 (en) | 2021-06-09 | 2021-06-09 | Treatment |
| GB2108224.3 | 2021-06-09 | ||
| PCT/GB2022/051442 WO2022258972A1 (en) | 2021-06-09 | 2022-06-09 | Nitroxoline for use in the treatment of cutaneous neurofibroma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240024175A true KR20240024175A (ko) | 2024-02-23 |
Family
ID=76838879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247000745A Pending KR20240024175A (ko) | 2021-06-09 | 2022-06-09 | 피부 신경섬유종의 치료에 사용하기 위한 니트록솔린 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240261276A1 (https=) |
| EP (1) | EP4351576A1 (https=) |
| JP (1) | JP2024520690A (https=) |
| KR (1) | KR20240024175A (https=) |
| CN (1) | CN117769419A (https=) |
| AU (1) | AU2022290019A1 (https=) |
| BR (1) | BR112023025789A2 (https=) |
| CA (1) | CA3221964A1 (https=) |
| GB (1) | GB202108224D0 (https=) |
| IL (1) | IL309177A (https=) |
| MX (1) | MX2023014530A (https=) |
| WO (1) | WO2022258972A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202116743D0 (en) * | 2021-11-19 | 2022-01-05 | Healx Ltd | Treatment |
| GB202218460D0 (en) * | 2022-12-08 | 2023-01-25 | Healx Ltd | Treatment |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3039822C (en) * | 2016-10-14 | 2026-02-17 | Wake Forest University Health Sciences | Compositions, cell constructs, and methods of making and using the same |
-
2021
- 2021-06-09 GB GBGB2108224.3A patent/GB202108224D0/en not_active Ceased
-
2022
- 2022-06-09 BR BR112023025789A patent/BR112023025789A2/pt unknown
- 2022-06-09 KR KR1020247000745A patent/KR20240024175A/ko active Pending
- 2022-06-09 MX MX2023014530A patent/MX2023014530A/es unknown
- 2022-06-09 AU AU2022290019A patent/AU2022290019A1/en active Pending
- 2022-06-09 US US18/567,829 patent/US20240261276A1/en active Pending
- 2022-06-09 EP EP22732622.0A patent/EP4351576A1/en active Pending
- 2022-06-09 WO PCT/GB2022/051442 patent/WO2022258972A1/en not_active Ceased
- 2022-06-09 CA CA3221964A patent/CA3221964A1/en active Pending
- 2022-06-09 CN CN202280040639.5A patent/CN117769419A/zh active Pending
- 2022-06-09 IL IL309177A patent/IL309177A/en unknown
- 2022-06-09 JP JP2023574531A patent/JP2024520690A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| GB202108224D0 (en) | 2021-07-21 |
| CN117769419A (zh) | 2024-03-26 |
| CA3221964A1 (en) | 2022-12-15 |
| EP4351576A1 (en) | 2024-04-17 |
| AU2022290019A1 (en) | 2023-12-14 |
| MX2023014530A (es) | 2024-04-10 |
| WO2022258972A1 (en) | 2022-12-15 |
| JP2024520690A (ja) | 2024-05-24 |
| BR112023025789A2 (pt) | 2024-02-27 |
| US20240261276A1 (en) | 2024-08-08 |
| IL309177A (en) | 2024-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102698911B1 (ko) | 근육 질환을 예방하거나 치료하기 위한 조성물 및 방법 | |
| KR100891568B1 (ko) | 나트륨 채널 차단 화합물인 테트로도톡신의 무통 제공 방법 | |
| KR20080035630A (ko) | 암의 치료 | |
| KR20240024175A (ko) | 피부 신경섬유종의 치료에 사용하기 위한 니트록솔린 | |
| Li et al. | Melatonin regulates microglial polarization to M2 cell via RhoA/ROCK signaling pathway in epilepsy | |
| KR20200101948A (ko) | 신경계 질환 치료제 | |
| US20250000852A1 (en) | Nitroxoline for use in the treatment or prevention of a plexiform neurofibroma | |
| Wang et al. | PARP inhibitor rescues hearing and hair cell impairment in Cx26‐null mice | |
| CN121197400A (zh) | 用于治疗血管性埃勒斯-当洛斯综合征和有关障碍的组合物和方法 | |
| WO2021260387A1 (en) | Mmp-9 and mmp-12 inhibition for treating spinal cord injury or related injury to neurological tissue | |
| US8633250B2 (en) | Cell repair and regeneration by suramin and related polysulfonated napthylureas | |
| Wang et al. | Loss of Sfrp2 contributes to the neurological disorders related with morphine withdrawal via Wnt/β-catenin signaling | |
| US20160000804A1 (en) | Inhibitors of na(v) 1.9 channel activity and uses thereof for treating pain | |
| KR20150083167A (ko) | 메틸렌 블루를 포함하는 감각신경성 난청의 치료 또는 예방용 약학 조성물 | |
| US12599617B2 (en) | Methods of treating head and neck cancers with hemp extract | |
| US20180086827A1 (en) | Therapeutics and methods of treating fibroproliferative diseases | |
| Tan et al. | GPR40 Attenuates Age-Related Macular Degeneration by Suppressing Retinal Microglial NLRP3 Inflammasome Activation Via ERK Signaling | |
| CN120815085A (zh) | 赛沃替尼在制备肌腱病治疗药物中的应用和一种药物 | |
| JP6510523B2 (ja) | １つ以上の神経再生ペプチドを用いて癲癇または発作を治療または予防する方法 | |
| Mueller | Neuroprotective properties of sigma-1 receptor in glaucoma | |
| CA3149702A1 (en) | Treatment of fragile x syndrome | |
| Wu et al. | Inhibition of connexin 36 decreases seizure activity in the Kainic acid-induced rat model of epilepsy | |
| Yaoa et al. | Enhancing mitophagy by ligustilide through BNIP3-LC3 interaction attenuates | |
| HK1174565B (en) | Method of treating scars and ss-catenin-mediated disorders using nefopam compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20240108 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20250530 Comment text: Request for Examination of Application |